All In Biotech

Drug Trial Radar · NCT07182838

Proof-of-Concept Clinical Pharmacology Trial for HIV Antigen Presentation Therapeutic Biologic Mix

Conducting an Initial Small, Controlled Clinical Pharmacology Trial to Assess for Therapeutic Biologics Activity (Proof-of-Concept) That Suggests the Potential for Clinical Benefits of HIV (+) Patients

Last checked: Nov 20, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Oct 5, 2026

Primary completion

Jun 18, 2027

Study completion Oct 28, 2027

Sponsor

Sponsor type
Industry
Collaborators
UnitedHealthcare
First posted
Sep 19, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Health services research
FDA-regulated drug
Yes
Who can join
All sexes, from 24 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Conducting an initial small, controlled clinical pharmacology trial to assess for therapeutic biologics activity (proof-of-concept) that suggests the potential for clinical benefit of HIV (+) patients 1. Treat Infection of Multiple Gene Mutation HIV Virus Strains. 2. Activate Human Antigen Presentation Reaction to HIV Specific Antigen. 3. The human antigen presenting cells (APCs) can take up and process HIV target antigen protein into small peptide fragments, and then HIV virus can be killed by APCs directly.

Conditions

  • HIV Infections

Interventions

  • HIV Therapeutic Biologic Mix - HIV GP160 plus BCG Vaccine Mix for percutaneous useBiological

    * By the percutaneous route with the multiple puncture device * HIV GP160 0.1 mg x 1 mL plus BCG Organism 50 MG Mix

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of HIV (+) Participants:Time frame: Duration up to 4 weeks
  2. Rate of Positive HIV nucleic acid:Time frame: Duration up to 4 weeks
  3. Rate of Negative HIV nucleic acid:Time frame: Duration up to 4 weeks
  4. 20 HIV (+) Participants with IGRA blood test with HIV antigensTime frame: Duration up to 4 weeks
  5. 20 HIV (+) Participants with IGRA blood test with TB antigensTime frame: Duration up to 4 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Medicine Invention Design Incorporation - IORG0007849 - NPI 1023387701

    Rockville, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.